Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.46 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.46 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.46 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | MAOA | P21397 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 2/20 | 0.45 |
| ▸ | DRD1 | P21728 | 2/20 | 0.45 |
| ▸ | DRD3 | P35462 | 2/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | DRD5 | P21918 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 3/20 | 0.44 |
| ▸ | HTR2C | P28335 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7711222 | 0.89 | MTNR1A (0.44) | MTNR1AGRM5LMNASMN1; SMN2GRIN2D | |
| SCHEMBL15857872 | 0.87 | MTNR1A (0.43) | MTNR1AGRM5LMNASMN1; SMN2GRIN2D | |
| SCHEMBL12905332 | 0.81 | MTNR1A (0.48) | MTNR1ALMNASMN1; SMN2GRIN2DGRIN3B | |
| SCHEMBL12048949 | 0.79 | MTNR1A (0.43) | MTNR1AGRM5GRIN2DGRIN3BGRIN1 | |
| SCHEMBL20904046 | 0.78 | HTR2A (0.43) | MTNR1ALMNASMN1; SMN2GRIN2DGRIN3B | |
| SCHEMBL19864956 | 0.77 | MTNR1A (0.42) | MTNR1AGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL13102183 | 0.77 | MTNR1A (0.62) | MTNR1AGRM5LMNAGRIN2DGRIN3B | |
| SCHEMBL13068413 | 0.76 | GRIN2D (0.50) | MTNR1AGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL17114774 | 0.76 | NUDT1 (0.47) | MTNR1AGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL14525298 | 0.76 | GRIN2D (0.46) | MTNR1AGRIN2DGRIN3BGRIN1GRIN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 141 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | KUMQUAT BIOSCIENCES INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | KUMQUAT BIOSCIENCES INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230339952-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. | 2023-10-26 | — | — | US | disclosed |
| WO-2023205701-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | KUMQUAT BIOSCIENCES INC. (US) | 2023-10-26 | — | — | WO | disclosed |
| EP-3445762-B1 | SUBSTITUTED BICYCLIC HETEROCYCLIC COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-13 | — | — | EP | disclosed |
| US-20230210854-A1 | MONO- AND COMBINATION THERAPIES | RECURIUM IP HOLDINGS, LLC | 2023-07-06 | — | — | US | disclosed |
| US-20230210854-A1 | MONO- AND COMBINATION THERAPIES | RECURIUM IP HOLDINGS, LLC | 2023-07-06 | — | — | US | disclosed |
| US-20230054854-A1 | COMBINATIONS | RECURIUM IP HOLDINGS, LLC | 2023-02-23 | — | — | US | disclosed |
| US-20230008362-A1 | COMBINATIONS | RECURIUM IP HOLDINGS, LLC | 2023-01-12 | — | — | US | disclosed |
| WO-2022268066-A1 | PROTEIN DEGRADATION AGENT | 苏州开拓药业股份有限公司 | 2022-12-29 | — | — | WO | disclosed |
| WO-2009068322-A1 | SELECTIVE INHIBITION OF POLO-LIKE KINASE 1 | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENS CHAFTEN E.V. (DE) | 2009-06-04 | — | — | WO | disclosed |
| EP-2065039-A1 | Selective inhibition of Polo-like kinase 1 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2009-06-03 | — | — | EP | disclosed |
| US-20090105271-A1 | PYRIDYL SULFONAMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2009-04-23 | — | — | US | disclosed |
| US-20080261956-A1 | Substituted Phenols as Active Agents Inhibiting Vegf Production | PTC THERAPEUTICS, INC. | 2008-10-23 | — | — | US | disclosed |
| WO-2008055488-A1 | MICHAEL SYSTEMS AS TRANSGLUTAMINASE INHIBITORS | ZEDIRA GMBH (DE) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008052804-A1 | THIAZOLHYDRAZIDES FOR TREATMENT OF NEURODEGENERATIVE DISEASES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2008-05-08 | — | — | WO | disclosed |
| EP-1918286-A1 | Thiazolhydrazides for treatment of neurodegenerative diseases | MPG Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2008-05-07 | — | — | EP | disclosed |
| US-7351827-B2 | Substituted oxetanes, method of making, and method of use thereof | THE UNIVERSITY OF CONNECTICUT (US) | 2008-04-01 | — | — | US | disclosed |
| US-20080027067-A1 | Heterocyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-31 | — | — | US | disclosed |
| US-20070021442-A1 | HIV reverse transcriptase inhibitors | MERCK SHARP & DOHME CORP. | 2007-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11912708-B2 | Macrocyclic heterocycles and uses thereof | HRAS, KRAS, TP53 | MTNR1A 4856/4885GRM5 4237/4885LMNA 2455/4885 |
| US-20080027067-A1 | Heterocyclic derivatives as modulators of ion channels | TRPV1, KCNJ2, KCNN3 | MTNR1A 988/4885GRM5 261/4885LMNA 2366/4885 |
| US-20090105271-A1 | PYRIDYL SULFONAMIDES AS MODULATORS OF ION CHANNELS | KCNJ2, TRPV1, KCNJ1 | MTNR1A 1202/4885GRM5 321/4885LMNA 2580/4885 |
| US-20070021442-A1 | HIV reverse transcriptase inhibitors | POLRMT, RNGTT, POLR2E | MTNR1A 4547/4885GRM5 3832/4885LMNA 2183/4885 |
| US-20230054854-A1 | COMBINATIONS | WEE2, WEE1, BCL2 | MTNR1A 2294/4885GRM5 4070/4885LMNA 2810/4885 |
| US-20230210854-A1 | MONO- AND COMBINATION THERAPIES | TP53, BRCA1, MCL1 | MTNR1A 191/4885GRM5 1626/4885LMNA 3497/4885 |
| US-20080261956-A1 | Substituted Phenols as Active Agents Inhibiting Vegf Production | VEGFA, FLT4, FLT1 | MTNR1A 701/4885GRM5 3525/4885LMNA 4326/4885 |
| US-20230008362-A1 | COMBINATIONS | WEE2, WEE1, BCL2 | MTNR1A 2323/4885GRM5 4184/4885LMNA 2714/4885 |
| US-20230339952-A1 | MACROCYCLIC HETEROCYCLES AND USES THEREOF | HRAS, KRAS, TP53 | MTNR1A 4856/4885GRM5 4237/4885LMNA 2455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.